Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus - Seite 2

The preclinical work that supported this investigational new drug application has been published online in Molecular Therapy Nucleic Acids, a Cell Press partner journal. The paper (https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S ...22)00287-6), titled “Chimeric mRNA-based COVID-19 vaccine induces protective immunity against Omicron and Delta variants,” will appear in print in the December 2022 issue of the journal.

Sorrento plans to pursue more advanced mRNA vaccine strategies in the future with the Sofusa MuVaxx lymphatic delivery system. This proprietary microneedle system delivers vaccines intradermally and, in animal models with an mRNA vaccine candidate, demonstrated improved humoral immunity and superior cellular immunity with 1/10^th of the IM dose. This preclinical work has been accepted for publication by the Journal of Molecular Cell Biology (JMCB) (https://academic.oup.com/jmcb/advance-article/doi/10.1093/jmcb/mjac041 ...), “Delivering an mRNA vaccine using a lymphatic drug delivery device improves humoral and cellular immunity against SARS-CoV-2.” In these preclinical studies using MuVaxx, immune responses were elicited and maintained at a 10-fold dose reduction compared to traditional IM administration as measured by anti-spike antibodies, cytokine-producing CD8 T cells, neutralizing antibodies. Remarkably, a 4-fold elevated T cell response was also observed in MuVaxx administered vaccination compared to that of IM administered vaccination. This microneedle system delivers the vaccine into at the epidermal/dermal boundary and is virtually pain free. These next generation advances may provide important alternative to the vaccines in the U.S. and enable improved access globally in countries like Mexico, Brazil, and China where mRNA-based vaccines are not readily available.

About Sorrento Therapeutics, Inc. 

Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as next-generation tyrosine kinase inhibitors (“TKIs”), fully human antibodies (“G-MAB library”), immuno-cellular therapies (“DAR-T”), antibody-drug conjugates (“ADCs”), and oncolytic virus (“Seprehvec”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including STI-1557, STI-1558, COVISHIELD, COVIDROPS and COVI-MSC; and diagnostic test solutions, including COVIMARK.